| Literature DB >> 29217764 |
Joke Tommelein1,2, Elly De Vlieghere1,2, Laurine Verset3, Elodie Melsens2,4, Justine Leenders5, Benedicte Descamps6, Annelies Debucquoy7, Christian Vanhove6, Patrick Pauwels8, Christian P Gespach9, Anne Vral10, Astrid De Boeck11, Karin Haustermans7, Pascal de Tullio5, Wim Ceelen2,4, Pieter Demetter3, Tom Boterberg1,2, Marc Bracke1,2, Olivier De Wever12,2.
Abstract
Preoperative radiotherapy (RT) is a mainstay in the management of rectal cancer, a tumor characterized by desmoplastic stroma containing cancer-associated fibroblasts (CAF). Although CAFs are abundantly present, the effects of RT to CAF and its impact on cancer cells are unknown. We evaluated the damage responses of CAF to RT and investigated changes in colorectal cancer cell growth, transcriptome, metabolome, and kinome in response to paracrine signals emerging from irradiated CAF. RT to CAF induced DNA damage, p53 activation, cell-cycle arrest, and secretion of paracrine mediators, including insulin-like growth factor-1 (IGF1). Subsequently, RT-activated CAFs promoted survival of colorectal cancer cells, as well as a metabolic switch favoring glutamine consumption through IGF1 receptor (IGF1R) activation. RT followed by IGF1R neutralization in orthotopic colorectal cancer models reduced the number of mice with organ metastases. Activation of the downstream IGF1R mediator mTOR was significantly higher in matched (intrapatient) samples and in unmatched (interpatient) samples from rectal cancer patients after neoadjuvant chemoradiotherapy. Taken together, our data support the notion that paracrine IGF1/IGF1R signaling initiated by RT-activated CAF worsens colorectal cancer progression, establishing a preclinical rationale to target this activation loop to further improve clinical responses and patient survival.Significance: These findings reveal that paracrine IGF1/IGF1R signaling promotes colorectal cancer progression, establishing a preclinical rationale to target this activation loop. Cancer Res; 78(3); 659-70. ©2017 AACR. ©2017 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29217764 DOI: 10.1158/0008-5472.CAN-17-0524
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701